Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations
- Blocking/Neutralizing [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- AF626 - Provider product page
- Provider
- R&D Systems
- Product name
- Human TRANCE/TNFSF11/RANK L Antibody
- Antibody type
- Polyclonal
- Description
- Antigen Affinity-purified. Detects human TRANCE/TNFSF11/RANK L in direct ELISAs and Western blots. In direct ELISAs, less than 30% cross-reactivity with recombinant mouse TRANCE is observed.
- Reactivity
- Human
- Host
- Goat
- Conjugate
- Unconjugated
- Antigen sequence
O14788
- Isotype
- IgG
- Vial size
- 100 ug
- Concentration
- LYOPH
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references A Modified Glycosaminoglycan, GM-0111, Inhibits Molecular Signaling Involved in Periodontitis.
Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma.
Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.
Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.
Savage JR, Pulsipher A, Rao NV, Kennedy TP, Prestwich GD, Ryan ME, Lee WY
PloS one 2016;11(6):e0157310
PloS one 2016;11(6):e0157310
Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma.
Buckle CH, De Leenheer E, Lawson MA, Yong K, Rabin N, Perry M, Vanderkerken K, Croucher PI
PloS one 2012;7(8):e41127
PloS one 2012;7(8):e41127
Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.
Grimaud E, Soubigou L, Couillaud S, Coipeau P, Moreau A, Passuti N, Gouin F, Redini F, Heymann D
The American journal of pathology 2003 Nov;163(5):2021-31
The American journal of pathology 2003 Nov;163(5):2021-31
Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.
Grimaud E, Soubigou L, Couillaud S, Coipeau P, Moreau A, Passuti N, Gouin F, Redini F, Heymann D
The American journal of pathology 2003 Nov;163(5):2021-31
The American journal of pathology 2003 Nov;163(5):2021-31
No comments: Submit comment
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- Osteoclast-Like Cell Form-ation Induced by TRANCE/ TNFSF11/RANK L and Neutralization by Human TRANCE/TNFSF11/RANK L Antibody. In the presence of Recombinant Mouse M-CSF (20 ng/mL, Catalog # 416-ML), Recombinant Human TRANCE/ TNFSF11/RANK L (Catalog # 390-TN) induces osteoclast-like cell formation in RAW 264.7 mouse macrophages in a dose-dependent manner (orange line), as measured by TRAP (tartrate-resistant acid phosphatase) solution assay. Under these conditions, osteoclast-like cell formation elicited by Recombinant Human TRANCE/TNFSF11/ RANK L (10 ng/mL) is neutral-ized (green line) by increasing concentrations of Goat Anti-Human TRANCE/TNFSF11/ RANK L Antigen Affinity-purified Poly-clonal Antibody (Catalog # AF626). The ND50 is typically 0.01-0.04 µg/mL.